How should clinicians combat coronavirus disease (COVID-19) in their practice settings?
The risk for cardiovascular disease is grossly underestimated and may account for the disproportionately high percentage of cardiovascular-related deaths in this population.
Familial hypercholesterolemia is one of the most clinically relevant monogenic disorders contributing to the development of atherosclerotic cardiovascular disease.
Excess adiposity, increasingly a worldwide pathological condition, represents a major risk factor for most chronic diseases, including colorectal cancer.
We make a promise to do good by our patients, but what does it mean to do harm? Should we include socioeconomic harm in this discussion?
Electrocardiography is a valuable tool to assess left ventricular hypertrophy, which has been associated with the development of major cardiovascular events.
Emerging studies aim to better understand therapeutic interventions that may mitigate increased CVD risk in patients with RA.
Although mortality rates associated with cardiovascular disease have decreased significantly in high-income countries in recent decades, substantial challenges related to CVD treatment and outcomes persist in rural areas.
The incidence of atrial fibrillation is predicted to double by 2045. With this projected increase, it is important that clinicians have access to the latest screening and diagnostic tools to prevent thromboembolic complications.
Researchers find automated CT perfusion is an important tool in the triage and treatment decision making in acute ischemic stroke.